Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 1 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
VILMORIN & CIE is currently managing 5 pending office actions, all of which are situated within the Biotechnology & Pharmaceuticals technology area. All 5 pending office actions are being handled by 1 distinct art unit, which indicates a technical concentration in a specific niche. Despite this concentration in 1 distinct art unit, the company is interacting with 3 distinct examiners.
KUBELIK, ANNE R is the busiest examiner for the portfolio, currently overseeing 2 pending office actions. While she handles a portion of the work, the remaining actions are distributed among the other 3 distinct examiners. This means that while the art unit provides a consistent institutional environment, the company must still navigate the individual preferences of the examiners. Practitioners should look for consistency in the art unit's policies while tailoring their arguments to the specific styles of KUBELIK, ANNE R and her colleagues. The 2 pending office actions under this examiner represent a point of focus within the broader Biotechnology & Pharmaceuticals workload.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (75%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUBELIK, ANNE R | 2 | 75.8% | -1.1% |
| ORDAZ, CHRISTIAN JOSE | 1 | 66.7% | +78.6% |
| MCWILLIAMS, KELSEY LYNN | 1 | 89.2% | +5.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18656137 | RESISTANCE TO ToLCNDV IN SQUASH | KUBELIK, ANNE R | 23d overdue |
| 18907400 | CUCURBITA WITH DETERMINATE GROWTH HABIT | KUBELIK, ANNE R | — |
| 18853670 | TOLERANCE TO CGMMV IN CUCUMBER | ORDAZ, CHRISTIAN JOSE | — |
| 18294738 | RESISTANCE TO LEVEILLULA TAURICA IN PEPPER | MCWILLIAMS, KELSEY LYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18853670 | TOLERANCE TO CGMMV IN CUCUMBER | ORDAZ, CHRISTIAN JOSE | — |
| Art Unit | Apps |
|---|---|
| 1663 | 4 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18907400 | CUCURBITA WITH DETERMINATE GROWTH HABIT | KUBELIK, ANNE R | 1663 | §102§112 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18853670 | TOLERANCE TO CGMMV IN CUCUMBER | ORDAZ, CHRISTIAN JOSE | 1663 | §101§102§112 | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18656137 | RESISTANCE TO ToLCNDV IN SQUASH | KUBELIK, ANNE R | 1663 | §101§112 | Final Rejection | 23d overdue | Pending | May 06, 2024 |
| 18294738 | RESISTANCE TO LEVEILLULA TAURICA IN PEPPER | MCWILLIAMS, KELSEY LYNN | 1663 | §101§102§112 | Non-Final OA | — | Pending | Feb 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVILMORIN & CIE has 4 pending office actions as of October 2026, spread across 1 art units and 3 examiners.
Anne R Kubelik has the most, with 2 of VILMORIN & CIE's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
